Abstract
Anemia associated with cancer and cancer therapy is a common and important issue in the treatment of patients with malignant disease. Conventionally, blood transfusions are used to treat severe cancer-related anemia. Short- and long-acting preparations of recombinant human erythropoiesis-stimulating agents (ESAs) offer an alternative treatment option. Multiple studies and subsequent meta-analyses have demonstrated that ESA treatment increases hemoglobin levels and reduces the likelihood of transfusion for a proportion of treated patients. However, studies that attempted to evaluate whether ESAs improve tumor response and survival have generated conflicting evidence. Results of smaller trials reporting improved survival outcomes were contradicted by large randomized controlled trials that reported more deaths in patients receiving ESAs. In addition, there is strong evidence that cancer patients receiving ESAs have an increased risk of thromboembolic and cardiovascular events. We herein review the main meta-analyses published in the field, their strengths and weaknesses, their contribution to patient management and future perspectives for systematic reviews.
Journal Section:
Editor's choice
References
1.
Knight K, Wade S, Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116:11S–26S.
[PubMed]
2.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–2306.
[PubMed]
3.
Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–1634.
[PubMed]
4.
Ludwig H, Strasser K: Symptomatology of anemia. Semin Oncol 2001;28:7–14.
[PubMed]
5.
Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214–2221.
[PubMed]
6.
Goodnough LT: Risks of blood transfusion. Anesthesiol Clin North America 2005;23:241–252.
[PubMed]
7.
Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J: Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79–89.
[PubMed]
8.
Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G: Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290–2297.
[PubMed]
9.
Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: Oncology Drugs Advisory Committee, 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf.
10.
Dmoszynska A, Kloczko J, Rokicka M, Hellmann A, Spicka I, Eid JE: A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy. Haematologica 2007;92:493–501.
[PubMed]
11.
Osterborg A, Steegmann JL, Hellmann A, Couban S, Mayer J, Eid JE: Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin’s lymphoma receiving combination chemotherapy. Br J Haematol 2007;136:736–744.
[PubMed]
12.
Krzakowski M: Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy. Clin Oncol (R Coll Radiol) 2008;20:705–713.
[PubMed]
13.
Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;67:39–61.
[PubMed]
14.
Quirt I, Micucci S, Moran LA, Pater J, Browman G: Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control 1997;1:241–248.
[PubMed]
15.
Marsh WA, Rascati KL: Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clin Ther 1999;21:1443–1455.
[PubMed]
16.
Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G: Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264–1273.
[PubMed]
17.
Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V: An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009;115:706–715.
[PubMed]
18.
Lambin P, Ramaekers BL, van Mastrigt GA, Van den Ende P, de Jong J, De Ruysscher DK, Pijls-Johannesma M: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009;3:CD006158.
19.
Cella D, Kallich J, McDermott A, Xu X: The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979–986.
[PubMed]
20.
Minton O, Richardson A, Sharpe M, Hotopf M, Stone P: A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008;100:1155–1166.
[PubMed]
21.
Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, Gordon MS, Lichtin AE, Wade JL 3rd, Woolf S, Aronson N: Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204–1214.
[PubMed]
22.
Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489–498.
[PubMed]
23.
Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C: A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1–220.
[PubMed]
24.
Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708–714.
[PubMed]
25.
Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N: Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Rockville, Agency for Healthcare Research and Quality, 2006, www.effectivehealthcare.ahrq.gov/reports/final.cfm.
26.
Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180: E62–E71.
[PubMed]
27.
Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT: Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801–831.
[PubMed]
28.
Couture F, Turner AR, Melosky B, Xiu L, Plante RK, Lau CY, Quirt I: Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005;10:63–71.
[PubMed]
29.
Clark O, Adams JR, Bennett CL, Djulbegovic B: Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2:23.
[PubMed]
30.
Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA: Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838–2347.
[PubMed]
31.
Sackett DL, Deeks JJ, Altman DG: Down with odds ratios! Evidence-Based Medicine 1996;1:164–166.
32.
Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407.
33.
Harbord RM, Egger M, Sterne JA: A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25:3443–3457.
[PubMed]
34.
Duval S: The Trim and Fill Method. Publication Bias in Meta-Analysis – Prevention, Assessment and Adjustments. Chichester, Wiley, 2005, pp 127–144.
35.
Carpenter JR, Schwarzer G, Ruecker G, Kuenstler R: Empirical evaluation showed that the Copas selection model provided a useful summary in 80% of meta-analyses. J Clin Epidemiol 2009;62:624–631.
[PubMed]
36.
Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983–2989.
[PubMed]
37.
Egger M, Smith GD: Meta-analysis – potentials and promise. BMJ 1997;315:1371–1374.
[PubMed]
38.
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, Mckoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–924.
[PubMed]
39.
Aapro M, Scherhag A, Burger HU: Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2,301 patients. Br J Cancer 2008;99:14–22.
[PubMed]
40.
Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301–315.
[PubMed]
41.
Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008;26:592–598.
[PubMed]
42.
Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF: Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342–2349.
[PubMed]
43.
Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, Williamson PR: The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
[PubMed]
44.
Vaupel P, Mayer A: Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005;12:5–10.
[PubMed]
45.
Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P: Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45–50.
[PubMed]
46.
Kelleher DK, Mattheinsen U, Thews O, Vaupel P: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728–4734.
[PubMed]
47.
Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752–756.
[PubMed]
48.
Silver DF, Piver MS: Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999;73:280–284.
[PubMed]
49.
Thews O, Kelleher DK, Vaupel P: Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358–1361.
[PubMed]
50.
Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358–1362.
[PubMed]
51.
Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–2874.
[PubMed]
52.
Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–1260.
[PubMed]
53.
Overgaard J Sr, Hoff CM, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen LJ, Evensen JF, Danish Head and Neck Cancer Group (DAHANCA): Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): final outcome of the DAHANCA 10 trial (abstract 6007). 2009 ASCO Annual Meeting. http://www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=65&abstractID=35348.
54.
Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459–460.
[PubMed]
55.
Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5865–5868.
[PubMed]
56.
Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA: Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040–1050.
[PubMed]
57.
Luksenburg H, Weir A, Wager R: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. ODAC Meeting, 2004. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2_04.pdf.
58.
FDA Briefing Document. Oncologic Drug Advisory Committee, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf.
59.
Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004;57:683–697.
[PubMed]
60.
Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1–30.
[PubMed]
61.
Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI: Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002;21:371–387.
[PubMed]
62.
Stern JM, Simes RJ: Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640–645.
[PubMed]
63.
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532–1542.
[PubMed]
64.
Simmonds MC, Higgins JP: Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat Med 2007;26:2982–2999.
[PubMed]
65.
Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG: Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941–6948.
[PubMed]
66.
Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU: Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 2006;95:1467–1473.
[PubMed]
67.
Aapro M, Osterwalder B, Scherhag A, Burger HU: Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009;101:1961–1971.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
